Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) saw a significant decline in short interest in October. As of October 31st, there was short interest totalling 2,461,720 shares, a decline of 12.1% from the October 13th total of 2,800,014 shares. Currently, 7.8% of the company’s stock are short sold. Based on an average daily volume of 294,067 shares, the short-interest ratio is presently 8.4 days.
Shares of Asterias Biotherapeutics (AST) opened at $2.30 on Wednesday. Asterias Biotherapeutics has a 12-month low of $2.20 and a 12-month high of $5.80.
Asterias Biotherapeutics (NYSEAMERICAN:AST) last released its earnings results on Monday, August 14th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.18). The business had revenue of $0.32 million for the quarter, compared to the consensus estimate of $1.25 million. Asterias Biotherapeutics had a negative return on equity of 86.25% and a negative net margin of 2,762.03%.
A number of analysts have recently commented on AST shares. Zacks Investment Research upgraded Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a report on Wednesday, October 25th. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Asterias Biotherapeutics in a report on Monday, October 2nd. Finally, ValuEngine lowered Asterias Biotherapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 4th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Asterias Biotherapeutics has a consensus rating of “Buy” and an average target price of $9.19.
Asterias Biotherapeutics Company Profile
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.